HCA Red Flag: Novo Nordisk upgrades again, and Wegovy pill beats expectations by 17% (AI)
HC Andersen Capital
Summary
- Novo Nordisk's Wegovy pill sales exceeded expectations by 17%, generating 5.4 BDKK compared to the expected 4.6 BDKK, prompting a need to raise estimates for the pill and for 2026.
- The company's operating profit guidance for the year only reflects Q3's extra earnings, with Q4 estimates remaining unchanged due to increased spending on the CagriSema launch in the US.
- Sales guidance has been raised to a range of minus 2% to plus 2%, surpassing analyst expectations, with a gross margin of 82.1% driven by restructuring savings and favorable currency effects.
- CFO Karsten Munk Knudsen will step down at year-end, succeeded by Luigi La Corte, as the company prepares for US price cuts and 2027 guidance.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in Danish 04/11/2026, 06:38 GMT. Give feedback here.
Red Flag · First reading of the financial statements · AI-generated content
HCA Red Flag: Novo Nordisk upgrades again, and Wegovy pill beats expectations by 17% (AI)
Novo Nordisk (NOVO B) · Q3 2026 · November 4
Share down 11% in 3 months, 34% below the year's high
| Overall assessment | Positive assessment |
| Positive assessment | Balanced | Negative assessment |
The obesity pill Wegovy generated sales of 5.4 BDKK vs. the expected 4.6 BDKK, pointing toward a higher open as estimates for the pill and for 2026 need to be raised. The raised operating profit guidance only incorporates the quarter's extra earnings, leaving Q4 in line with analyst expectations.
Red flags in the financial statements
Profit guidance only lifts the year by the quarter's profit
Implicit Q4: 27.0 BDKK · Est. 27.1 BDKK
The midpoint of the new guidance only incorporates Q3's extra earnings, partly because Novo is increasing spending on the launch of CagriSema, its next weight-loss injection, in the US. Estimates for the fourth quarter therefore have nothing to gain.
The sales boost partly relies on rebate effects without amounts
Actual 79.2 BDKK · Est. 73.2 BDKK
In the US, retroactive rebate adjustments provided another positive boost, and Ozempic outside the US received a one-off adjustment, but Novo disclosed no amounts. Consequently, the 8% boost does not fully carry over into next year's estimates.
CFO leaves Novo at year-end
New: steps down on December 31
Karsten Munk Knudsen, CFO since 2018, is leaving Novo at year-end and will be succeeded by Luigi La Corte from skincare company Galderma. The transition comes ahead of US price cuts in January and the first guidance for 2027.
Green flags in the financial statements
Wegovy pill sells 17% above expectations
Actual 5,394 MDKK · Est. 4,615 MDKK
The obesity pill Wegovy received ~3.6 million US prescriptions in the quarter and already generated sales of 1.2 BDKK outside the US. With eight countries now and over 20 in 2027, estimates for the pill need to be raised.
Sales guidance raised above analyst expectations
Now: minus 2 to plus 2% · Previously: minus 6 to 0%
The midpoint of 0% at constant exchange rates – meaning excluding currency effects – is above analysts' decline of 2.1%. Fourth-quarter sales must therefore exceed expectations by ~2.0 BDKK, driving up sales estimates for 2026.
Gross margin lands clearly above expectations
Adj. 82.1% · Est. 80.2%
Savings from last year's restructuring, higher productivity, and favorable currency lifted the margin, even though US prices fell. If the level holds, analysts will have a higher baseline for earnings in 2027.
Disclaimer: This is an HCA AI-generated research commentary based solely on the company's published financial statements. The commentary does not constitute investment consulting and should not be the sole basis for investment decisions. Investing in shares involves the risk of loss. Seek professional advice. /HC Andersen Capital, 07:37, November 4, 2026